<DOC>
	<DOCNO>NCT02181101</DOCNO>
	<brief_summary>This open-label , multicenter , 2x2 factorial design , randomize control , Phase III study compare disease free survival randomisation patient treat 3 cycle Epirubicin-Fluorouracil-Cyclophosphamide ( FEC ) -chemotherapy , follow 3 cycle Docetaxel ( Doc ) -chemotherapy versus 3 cycle Epirubicin-Fluorouracil-Cyclophosphamide ( FEC ) , follow 3 cycle Gemcitabine-Docetaxel ( DocGemzar ) -chemotherapy , compare disease free survival randomisation patient treat 2 year Zoledronate versus 5 year Zoledronate patient early primary breast cancer . Patients required histopathological proof axillary lymph node metastasis ( pN1-3 ) high risk node negative , define : 'pT≥2 histopathological grade 3 , age ≤ 35 negative hormone receptor ' , allow evidence distant disease . Patients enter study later 6 week complete resection primary tumor . No antineoplastic treatment surgical treatment , define cytotoxic endocrine treatment radiotherapy allow prior study entry course study . After surgery , lead R0 resection invasive intraductal component primary tumor , patient randomize one follow treatment : First randomization AA : 3 cycle 5-Fluorouracil 500 mg/m² i.v . body surface area Epirubicin 100 mg/m² i.v . Cyclophosphamide 500 mg/m² i.v. , ( FEC100 ) , administer day 1 , repeat day 22 , subsequently follow 3 cycle Docetaxel 75 mg/m² body surface area i.v . ( Doc ) , Gemcitabine 1000 mg/m² i.v . ( 30 min infusion ) ( Gemzar ) , administer day 1 , follow Gemcitabine 1000 mg/m² i.v . ( 30 min infusion ) day 8 , repeat day 22 AB : 3 cycle 5-Fluorouracil 500 mg/m² i.v . body surface area Epirubicin 100 mg/m² i.v . Cyclophosphamide 500 mg/m² i.v. , ( FEC100 ) , administer day 1 , repeat day 22 , subsequently follow 3 cycle Docetaxel 100 mg/m² body surface area i.v . ( Doc ) , administer day 1 , repeat day 22 Second randomization B BA : Zoledronic acid 4 mg i.v. , every 3 month duration two year , subsequently follow zoledronic acid 4 mg i.v. , every 6 month duration additional three year BB : Zoledronic acid 4 mg i.v. , every 3 month duration two year During zoledronic acid treatment period , patient receive 500 mg Calcium p.o . qid 400 i.E . Vitamin D p.o . qid . Patients positive hormone receptor status ( ≥ 10 % positively stain cell estrogen and/or progesterone ) primary tumor receive Tamoxifen treatment 20 mg p.o . per day 2 year , end chemotherapy . Subsequent chemotherapy , postmenopausal patient positive hormone receptor status treat Anastrozole ( Arimidex® ) 1 mg p.o . additional 3 year , premenopausal patient continue Tamoxifen treatment additional 3 year . In addition tamoxifen , patient positive hormone receptor status primary tumor age 40 restart menstrual bleeding within 6 month completion cytostatic treatment premenopausal hormone level define receive Goserelin ( Zoladex® ) 3.6 mg subcutaneously every 4 week period 2 year follow chemotherapy . Premenopausal endocrine status assume , follow serum level meet : Luteinizing hormone ( LH ) &lt; 20 mIE/ml , follicle stimulate hormone ( FSH ) &lt; 20 mIE/ml estradiol ( E2 ) &gt; 20 pg/ml . Endocrine therapy start end chemotherapy . All patient breast conserve therapy 3 axillary lymph node metastases follow case mastectomy : - T3/T4-carcinoma - T2-carcinoma &gt; 3 cm - multicentric tumor growth - lymphangiosis carcinomatosa vessel involvement - involvement pectoralis fascia safety margin &lt; 5 mm . receive adjuvant radiotherapy .</brief_summary>
	<brief_title>Simultaneous Study Gemcitabine-Docetaxel Combination Adjuvant Treatment , Well Extended Bisphosphonate Surveillance-Trial</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Zoledronic acid</mesh_term>
	<mesh_term>Diphosphonates</mesh_term>
	<criteria>Primary epithelial invasive carcinoma breast pT14 , pM0 Histopathological proof axillary lymph node metastasis ( pN13 ) high risk pN0/NX , define : 'pT ≥ 2 histopathological grade 3 age ≤ 35 negative hormone receptor status ' Complete resection primary tumor margin resection free invasive carcinoma 6 week ago Females ≥ 18 year age Performance Status ≤ 2 Eastern Cooperative Oncology Group ( ECOG ) Scale Adequate bone marrow reserve : leucocytes ≥ 3.0 x 10^9/l platelet ≥ 100 x 10^9/l Bilirubin within one fold reference laboratory 's normal range , aspartate aminotransferase ( ASAT ) ( serum glutamate oxalacetate transaminase , SGOT ) , alanine aminotransferase ( ALAT ) ( serum glutamate pyruvate transaminase , SGPT ) alkaline phosphatase ( AP ) within 1,5 fold reference laboratory 's normal range patient Intention regular followup visit duration study Ability understand nature study give write informed consent Inflammatory breast cancer Previous concomitant cytotoxic systemic antineoplastic treatment part allow within study History treatment disease affect bone metabolism ( e.g. , Paget 's disease , primary hyperparathyroidism ) Prior treatment bisphosphonates within last 6 month Severe renal insufficiency evidence creatinine clearance &lt; 30 ml/min calculate use CockcroftGault formula Second primary malignancy ( except situ carcinoma cervix adequately treat basal cell carcinoma skin ) Cardiomyopathy impair ventricular function ( New York Heart Association Functional Classification Class ( NYHA ) &gt; II ) , cardiac arrythmias influence leave ventricular ejection fraction ( LVEF ) require medication , history myocardial infarction angina pectoris within last 6 month , arterial hypertension control medication Any known hypersensitivity docetaxel , epirubicin , cyclophosphamide , fluorouracil , gemcitabine medication include study protocol Use investigational agent within 3 week prior inclusion Patients pregnancy breast feeding ( premenopausal woman anticonception assure : intra uterine device , surgical method sterilization , , hormone unsensitive tumor , oral , subcutaneous transvaginal hormonal , non estrogen contain contraceptive ) Current active dental problem include infection teeth jawbone ( maxilla mandibular ) ; dental fixture trauma , current prior diagnosis osteonecrosis jaw ( ONJ ) , expose bone mouth , slow healing dental procedure . Recent ( within 6 week ) plan dental jaw surgery ( e.g.. extraction , implant )</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>